Analysis of more than 111,000 participants shows 0.91% cancer detection rate with 87% accuracy in predicting tumor origin.
A large-scale study analyzing real-world performance of the Galleri multi-cancer early detection test has demonstrated the blood-based screening tool’s ability to detect cancer signals and predict their anatomical origin across diverse healthcare settings.
The study, published in Nature Communications, evaluated 111,080 participants across private practices, healthcare systems, and telemedicine platforms. Marc Matrana, MD, medical oncologist at the Ochsner Cancer Institute, served as lead author of the publication.
The Galleri test analyzes methylation patterns in cell-free DNA to detect cancer signals in healthy individuals. Key findings from the study include a cancer detection rate of 0.91%, with 1,011 cancers identified among all participants.
“This research represents a significant step forward in the fight against cancer,” says Matrana in a release. “The Galleri test has the potential to revolutionize cancer screening and early detection, improving outcomes and saving lives.”
High Accuracy in Cancer Signal Origin Prediction
The study demonstrated 87% accuracy in cancer signal origin prediction among cases with a reported cancer type. The median time from test results to cancer diagnosis was 39.5 days, indicating potential for faster diagnostic evaluations compared to traditional screening methods.
The research validates the test’s feasibility across multiple healthcare delivery models, suggesting broad applicability for clinical implementation. The blood-based approach offers a less invasive alternative to traditional cancer screening methods while providing information about potential tumor location.
Photo caption: Marc Matrana, MD, medical oncologist at the Ochsner Cancer Institute, was lead author of a new study on the multi-cancer early detection test
Photo credit: Ochsner Health
We Recommend for You:
